Abstract: A peptide fragment for treatment of cancer, a variant thereof, and a use thereof. A peptide fragment of VGLL1 and/or a variant thereof inhibits the proliferation and invasion of cancer cells, thereby exhibiting an excellent effect on the prevention and treatment of cancer.

Abstract: An inhaler includes a housing having one surface, the other surface opposite to the one surface, and a plurality of side surfaces connecting the one surface and the other surface, a mouthpiece which is disposed on the one side of the housing, a reservoir which is disposed inside the housing and stores an inhalable composition, a nozzle which extends from the mouthpiece to the reservoir, and a needle valve which is movably disposed inside the nozzle, when a suction force is not applied to the mouthpiece, the needle valve is maintained in a first state in which the nozzle is closed, and when a suction force is applied through the mouthpiece, the needle valve is switched into a second state in which the nozzle is opened.

Abstract: A pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

Abstract: A display device includes: a substrate; a first pixel electrode and a second pixel electrode on the substrate; a dummy pixel electrode between the first pixel electrode and the second pixel electrode, and to receive a dummy voltage; an emissive layer on the first pixel electrode, the second pixel electrode, and the dummy pixel electrode; and a common electrode on the emissive layer. The first pixel electrode is to receive a pixel voltage different from the dummy voltage.

Abstract: A new use of M-CSF or G-CSF for diagnosis or treatment of pulmonary fibrosis is disclosed. A marker for diagnosing the level of development or progression of pulmonary fibrosis contains M-CSF and/or G-CSF; and a composition for preventing or treating pulmonary fibrosis, contains an M-CSF inhibitor and a G-CSF inhibitor as active ingredients. The present inventors have ascertained that M-CSF and/or G-CSF is a marker for development or progression of pulmonary fibrosis, and have confirmed that a composition, which contains M-CSF and G-CSF and which binds to M-CSF and G-CSF so that the inherent mechanism thereof can be prevented, has an effect of significantly inhibiting myofibroblast hyperplasia or pulmonary fibrosis of the pulmonary cells, and thus the marker and the composition of the present disclosure are expected to be effectively usable for diagnosis, prevention or treatment of pulmonary fibrosis.

Abstract: A substrate transferring apparatus includes a support plate including an upper surface on which a substrate is configured to be seated, and a vacuum pad detachably coupled to the support plate and configured to vacuum suction the substrate to fix the substrate on the upper surface of the support plate, wherein the vacuum pad includes a suction area and a support protrusion surrounding the suction area, an upper surface of the support protrusion is at a higher vertical level than an upper surface of the suction area to support the substrate, and the upper surface of the support protrusion is inclined relative to horizontal.

Abstract: A dishwasher according to one embodiment may comprise a storage part for storing an object to be washed. The storage part comprises: a base in which a plurality of horizontal bars and a plurality of vertical bars intersect each other; a supporter protruding from the base; and a first holder mounted to the supporter and provided so as to be rotatable with respect to the supporter, wherein the first holder may be supported by the supporter so as to maintain a posture at a set angle with respect to the supporter.

Abstract: The present disclosure relates to a cell-penetrating peptide, an anticancer peptide, and a pharmaceutical composition for preventing or treating cancer including the same. The cell-penetrating peptide of the present disclosure can further improve a cancer cell growth inhibitory effect of anticancer peptides, especially cancer therapeutic peptides with improved anticancer activity by cyclic structures, and thus can be effectively applied to the prevention or treatment of various cancers.

Abstract: A white light emitting device and a display device using the same which can prevent a change in luminance due to change in viewing angle, improve color deviation, and lower a driving voltage at the same time, through a change in an internal stack structure and a thickness an emission-side electrode with regard to a vertical distance from a lower surface of the first electrode to a lower surface of the second electrode.

Abstract: Disclosed is a silver powder preparation method including a silver salt reduction step. The silver salt reduction step includes a reaction solution preparation step for preparing a first reaction solution and a second reaction solution and a precipitation step for allowing reaction between the first reaction solution and the second reaction solution to precipitate silver particles. The first reaction solution contains silver ions, ammonia, an alkali metal salt of an organic acid, and a phosphorous compound, and the second reaction solution contains a reducing agent. The content of the phosphorous compound and the reaction temperature of the precipitation step are adjusted so that the shrinkage rate of the silver powder is adjusted within a range of 5% to 20% at 500° C. when the reaction temperature is heated to 800° C. at a heating rate of 50° C./min.

Abstract: An oxide semiconductor thin film transistor and a method of forming the oxide semiconductor thin film transistor are provided. The oxide semiconductor thin film transistor can include a semiconductor layer including a channel region, a source region and a drain region; a first gate insulating layer on the semiconductor layer; a gate electrode on the first gate insulating layer; a second gate insulating layer on the gate electrode; an auxiliary electrode on the second gate insulating layer; an interlayer insulating layer on the auxiliary electrode; and a source electrode and a drain electrode on the interlayer insulating layer, wherein the source region and the drain region being disposed at both sides of the channel region, wherein the gate electrode overlapping with the channel region, and the auxiliary electrode overlapping with the gate electrode.

Abstract: The present invention relates to a prebiotic composition, a composition for improving gut microorganisms, a composition for improving gut health or gut function, a composition for alleviating, preventing, or treating inflammatory bowel disease or leaky gut syndrome, or a composition for alleviating, preventing, or treating obesity or metabolic disease, which each comprise a molokhia extract or a molokhia polymer fraction as an active ingredient to induce the proliferation of beneficial intestinal bacteria and to improve, prevent, or treat gut heath or gut function. In addition, the composition comprising a molokhia extract or a molokhia polymer fraction as an active ingredient can alleviate, prevent, or treat bowel disease or leaky gut syndrome.

Abstract: The present disclosure relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

Abstract: The present invention relates to a novel antibody library and an antibody-screening method using same. Having a human sequence-derived specific VH or VL scaffold, the antibody library according to the present invention exhibits high thermodynamic stability and enjoys the advantages of allowing high soluble expression as well as reversible folding. In addition, the antibody according to the present invention includes a variety of rationally controlled CDRs so as to exhibit high specificity and high affinity to all antigens and thus can be advantageously used for selecting an adequate candidate antibody against a target antigen.

Abstract: A fusion protein contains an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Abstract: Provided are an organic electric element having a first electrode, a second electrode, and at least an organic material layer formed between the first electrode and the second electrode, the organic material layer comprising an emitting layer and the emitting layer comprising a mixture of host materials which improves luminous efficiency, stability, and lifespan of the element; and an organic electronic device comprising the element.

Abstract: Discussed is a light emitting device including a first electrode and a second electrode facing each other, a hole transport layer, a first emission layer, and an electron transport layer sequentially disposed between the first electrode and the second electrode. In the transport layer, a first material of a metal halide and a second material of an n-type inorganic compound are included. The second material is included as a dopant in the first material. The hole transport layer can contain no organic material and can be amorphous.

Abstract: Provided are light-emitting organic nanoparticles containing an organic phosphor having a luminous efficiency of 80% or more, wherein the light-emitting organic nanoparticles has an average particle size of 100 to 170 nm and a standard deviation of particle sizes of 500 nm or less, a composition for a color conversion film including the same, and a color conversion film, a display device, and a light-emitting diode device manufactured using the same.